108 related articles for article (PubMed ID: 6686024)
1. [Chemical modification with beta-propiolactone as a general concept for the production of intravenously tolerable immunoglobulin preparations].
Stephan W
Beitr Infusionther Klin Ernahr; 1983; 11():20-5. PubMed ID: 6686024
[No Abstract] [Full Text] [Related]
2. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report.
Höckel M; Kaufmann R
J Perinat Med; 1986; 14(3):205-8. PubMed ID: 3783391
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro behaviour and in vivo efficacy of two 7S-immunoglobulin preparations for intravenous use.
Stephan W; Dichtelmüller H
Arzneimittelforschung; 1983; 33(11):1538-40. PubMed ID: 6686449
[TBL] [Abstract][Full Text] [Related]
4. [Beta-propiolactone as a sterilizing agent in the manufacture of intravenous immunoglobulin preparations].
Stephan W; Dichtelmüller H
Arzneimittelforschung; 1983; 33(9):1230-1. PubMed ID: 6416260
[TBL] [Abstract][Full Text] [Related]
5. [Properties and efficacy of a human immunoglobulin M preparation for intravenous administration].
Stephan W; Dichtelmüller H; Schedel I
Arzneimittelforschung; 1985; 35(6):933-6. PubMed ID: 4026919
[TBL] [Abstract][Full Text] [Related]
6. [Prevention and therapy using immunoglobulins].
Heide K; Schwick HG
Internist (Berl); 1974 Sep; 15(9):465-70. PubMed ID: 4609355
[No Abstract] [Full Text] [Related]
7. On the mutagenicity and immunogenicity of a beta-propiolactone-treated therapeutic IgG-preparation.
Pincus JH; Mortelmans K; Tanaka W; Stephan W; Lissner R
Arzneimittelforschung; 1981; 31(11):1924-8. PubMed ID: 6172136
[TBL] [Abstract][Full Text] [Related]
8. [Human i.v. immune globulin by chemical modification with beta-propiolactone/radiochemical study (author's transl)].
Stephan W; Fasold H
Arzneimittelforschung; 1980; 30(12):2090-3. PubMed ID: 7194066
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone.
Stephan W; Dichtelmüller H; Prince AM; Brotman B; Huima T
J Med Virol; 1988 Nov; 26(3):227-32. PubMed ID: 3144576
[TBL] [Abstract][Full Text] [Related]
10. Undegraded human immunoglobulin for intravenous use.
Stephan W
Vox Sang; 1975; 28(6):422-37. PubMed ID: 807036
[TBL] [Abstract][Full Text] [Related]
11. Requirements and characteristics of various immunoglobulin preparations for intravenous application.
Guencheva G
Z Gesamte Hyg; 1984 Jan; 30(1):21-3. PubMed ID: 6711042
[No Abstract] [Full Text] [Related]
12. A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin.
Mondorf AW; Stephan W; Uthemann H; Schuppan D; Lissner R
Arzneimittelforschung; 1981; 31(11):1928-30. PubMed ID: 6797445
[TBL] [Abstract][Full Text] [Related]
13. Various immunoglobulin preparations for intravenous use.
Morell A
Vox Sang; 1986; 51 Suppl 2():44-9. PubMed ID: 2945321
[TBL] [Abstract][Full Text] [Related]
14. [Production and properties of a new chemically modified i.v. immunoglobulin: Polyglobin].
Spilles C
Beitr Infusionther Klin Ernahr; 1983; 11():26-33. PubMed ID: 6686025
[No Abstract] [Full Text] [Related]
15. [Detection of beta-propiolactone by polarography].
Pellerin F; Letavernier JF
Ann Pharm Fr; 1974 Nov; 32(11):561-8. PubMed ID: 4462417
[No Abstract] [Full Text] [Related]
16. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome.
Pierangeli SS; Liu XW; Barker JH; Anderson G; Harris EN
Thromb Haemost; 1995 Nov; 74(5):1361-7. PubMed ID: 8607123
[TBL] [Abstract][Full Text] [Related]
17. Reconsideration of IgM-enriched intravenous immunoglobulin for neonatal sepsis.
Hall SL
Am J Dis Child; 1989 Jul; 143(7):766. PubMed ID: 2741843
[No Abstract] [Full Text] [Related]
18. Elimination and organ distribution of intravenously administered allogeneic and xenogeneic IgG modifications. (Standard IgG, F (ab)2-fragments and beta-propiolactone treated IgG) in dogs.
Ring J; Duswald KH; Bachmann T; von Scheel J; Stephan W; Brendel W
Res Exp Med (Berl); 1978 Sep; 173(3):209-18. PubMed ID: 364571
[TBL] [Abstract][Full Text] [Related]
19. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
Dichtelmüller H; Rudnick D; Breuer B; Gänshirt KH
Biologicals; 1993 Sep; 21(3):259-68. PubMed ID: 8117439
[TBL] [Abstract][Full Text] [Related]
20. [Experimental studies and clinical experiences with homologous tendon grafts preserved with beta-propiolactone].
Salamon A; Bálint J
Handchirurgie; 1980; 12(3-4):207-11. PubMed ID: 7037568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
